深圳市海普瑞药业集团股份有限公司第六届董事会第十八次会议决议公告
Shang Hai Zheng Quan Bao·2025-11-24 17:41

Group 1 - The company held its 18th meeting of the 6th Board of Directors on November 24, 2025, with all 7 directors participating in the voting [1] - The meeting approved the proposal to cancel the supervisory board and amend the Articles of Association and related governance systems, allowing the audit committee of the board to exercise the powers of the supervisory board [2][52] - The company will no longer have a supervisory board or supervisors, and the relevant rules regarding the supervisory board will be abolished [52] Group 2 - The board approved the proposal regarding the resignation of independent director Lü Chuan due to the expiration of his term, and the nomination of Pu Hong as a candidate for independent director [3][48] - Pu Hong's appointment as an independent director is subject to approval by the shareholders' meeting and review by the Shenzhen Stock Exchange [3][49] - The board expressed gratitude for Lü Chuan's contributions during his tenure as an independent director [48] Group 3 - The board proposed to convene the 2025 First Extraordinary General Meeting of Shareholders on December 16, 2025, to discuss the approved proposals [4][55] - The meeting will include both on-site and online voting, with specific timeframes for each [56][70] - The company will ensure compliance with relevant laws and regulations regarding the meeting and voting procedures [55][60] Group 4 - The company has revised its governance systems to enhance operational efficiency and protect the rights of investors, particularly minority shareholders [53] - New systems have been established, and some existing systems have been integrated or abolished to align with current regulations [53][54] - The amendments to the Articles of Association and governance systems will require approval at the upcoming shareholders' meeting [54]

Hepalink-深圳市海普瑞药业集团股份有限公司第六届董事会第十八次会议决议公告 - Reportify